Grandview Asset Management’s Biogen BIIB Stock Holding History

Grandview Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-151	Closed	-$42K	–	142
2021 Q1	$42K	Buy	+151	New	+$40.7K	0.02%	221

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Grandview Asset Management's BIIB Position: Q2 2021 in Review

Grandview Asset Management sold out of Biogen (BIIB) in Q2 2021, closing a stake of 151 shares — an estimated $42K sold.

Grandview Asset Management first reported a position in BIIB in Q1 2021 and held it in 1 quarter. The position peaked at $42K in Q1 2021. 1,106 funds tracked by Wall St. Rank hold BIIB as of Q2 2021.

Grandview Asset Management reported no remaining Biogen position as of Q2 2021 after selling out during the quarter.
Grandview Asset Management sold 151 Biogen shares in Q2 2021, an estimated $42K.
Grandview Asset Management first reported a position in Biogen in Q1 2021 and held it in 1 quarter.
Grandview Asset Management's Biogen position peaked at $42K in Q1 2021.
1,106 funds tracked by Wall St. Rank held Biogen as of Q2 2021.

Based on Grandview Asset Management's 13F filing for Q2 2021, filed 21 Jul 2021.